Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer’s disease psychosis


Acadia Pharmaceuticals Inc. ACAD, +3.94% said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a treatment for hallucinations and delusions associated with Alzheimer’s disease psychosis. The FDA’s Psychopharmacologic Drugs Advisory Committee will review Acadia’s Nuplazid at a meeting scheduled for 8:45 a.m. Eastern. About six million people living in the U.S. have Alzheimer’s disease, according to the Alzheimer’s Association and about 30% of those suffer from psychosis. Acadia shares have fallen 16% in the year to date, while the S&P 500 SPX, +0.22% has fallen 23%.

This article was originally published by Read the original article here.

Previous articleWWE investigating CEO Vincent McMahon for ‘alleged misconduct’
Next articleTE Connectivity board approves additional $1.5 billion share buyback program


Please enter your comment!
Please enter your name here